Protara: Six-Month NMIBC Treatment Data Bodes Well For Mid-2025 Catalyst
Portfolio Pulse from
Protara Therapeutics is advancing its TARA-002 treatment in phase 2 studies for non-muscle invasive bladder cancer and pediatric lymphatic malformations, with data expected by mid-2025. The global bladder cancer market is projected to grow significantly by 2034.
December 10, 2024 | 9:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Protara Therapeutics' TARA-002 is in phase 2 trials for bladder cancer and pediatric lymphatic malformations, with results expected by mid-2025. The bladder cancer market is projected to grow to $5.4 billion by 2034.
The advancement of TARA-002 in phase 2 trials and the expected growth of the bladder cancer market are positive indicators for Protara Therapeutics. Successful trial results could lead to significant market opportunities.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100